1. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002; 18(6 Suppl):S142–S146. PMID:
12569961.
Article
2. Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol. 2009; 59:366–381. PMID:
19488551.
Article
3. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002; 18(6 Suppl):S119–S124. PMID:
12569958.
Article
4. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003; 4:159–165. PMID:
14622713.
Article
5. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005; 20:1152–1160. PMID:
15954134.
Article
6. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005; 65:1423–1429. PMID:
16275831.
Article
7. Apostol C, Abdi S, Moeller-Bertram T, Smith HS, Argoff CE, Wallace M. Smith HS, editor. Botulinum toxins for the treatment of pain. Current therapy in pain. 2009. Philadelphia: Saunders;p. 489–498.
Article
8. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002; 18(6 Suppl):S125–S132. PMID:
12569959.
Article
9. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 2006; 102:509–516. PMID:
16428552.
Article
10. Göbel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91:195–199. PMID:
11275374.
Article
11. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, Botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005; 25:604–611. PMID:
15372199.
Article
12. Fishman LM, Konnoth C, Rozner B. Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. Am J Phys Med Rehabil. 2004; 83:42–50. PMID:
14709974.
Article
13. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. 2004; 83:198–202. PMID:
15043354.
Article
14. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006; 125:82–88. PMID:
16750294.
Article
15. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003; 61:774–778. PMID:
12856249.
Article
16. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005; 84:649–654. PMID:
16141740.
Article
17. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56:1290–1293. PMID:
11376175.
Article
18. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002; 18(6 Suppl):S155–S162. PMID:
12569963.
Article
19. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40:445–450. PMID:
10849039.
Article
20. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006; 26:790–800. PMID:
16776693.
Article
21. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004; 24:838–843. PMID:
15377314.
Article
22. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004; 44:801–805. PMID:
15330827.
Article
23. Freund BJ, Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. Clin J Pain. 2002; 18(6 Suppl):S163–S168. PMID:
12569964.
Article
24. Mahowald ML, Krug HE, Singh JA, Dykstra D. Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Botulinum toxin for osteoarticular pain. Botulinum toxin. Therapeutic clinical practice and science. 2009. Philadelphia: Saunders;p. 295–306.
Article
25. Smith PP, Smith CP. Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Botulinum toxin in the treatment of chronic pelvic pain syndromes. Botulinum toxin. Therapeutic clinical practice and science. 2009. Philadelphia: Saunders;p. 257–268.
Article
26. Hallett M. Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Potential new therapeutic indications for botulinum neurotoxins. Botulinum toxin. Therapeutic clinical practice and science. 2009. Philadelphia: Saunders;p. 367–372.
Article